Isomerase were approached by a biotech company looking to generate 100s mg quantities of a therapeutic polyketide macrolide.
• Solution: Targeted rational bioengineering and fermentation improvement
Initial assessment of the literature producing strain (a filamentous actinomycete bacteria) revealed low and inconsistent production (<1mg/L).
USP fermentation development, strain selection and targeted expression of a regulator gene rapidly increased the titre of product to >0.5g/L, sufficient to enable production of the required quantities. Fermentation and isolation was carried out in-house at Isomerase and material supplied of sufficient quantity and quality to enable further development.
If you would like to learn more about our capabilities then please get in contact with us here.
